Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06354660 · ClinicalTrials.gov registry record · Phase 3
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
A Phase 3 study of Diabetes Type 2, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 537
- Enrollment target
- 20
- Study locations
NCT06354660 is a Phase 3 study of Diabetes Type 2 that has completed, run by Eli Lilly and Company. The registered enrollment target is 537 participants, below the 717-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06354660, a Phase 3 study of Diabetes Type 2, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 537 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- Northeast Research Institute (NERI) - Fleming Island
- New Horizon Research Center - Miami
- Ezy Medical Research - Miami
- Clinical Research of Central Florida - Winter Haven
Arizona
- Scottsdale Clinical Trials - Scottsdale
- Tucson Clinical Research Institute - Tucson
California
- San Fernando Valley Health Institute - Canoga Park
- Ark Clinical Research - Long Beach
Pennsylvania
- Clinical Research of Philadelphia - Philadelphia
- Preferred Primary Care Physicians - Uniontown
Georgia
- Trinity Research Centers - Marietta
Kansas
- Cotton O'Neil Clinical Research Center - Topeka
Massachusetts
- NECCR PrimaCare Research - Fall River
Missouri
- Clinical Research Professionals - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2026-02-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06354660
The ClinicalTrials.gov registry entry for NCT06354660 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 537 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 717-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (25% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06354660 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06354660 about?
NCT06354660 is a clinical study titled "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)". The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
What is the current status of trial NCT06354660?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 537 participants. The study started on 2024-04-10. Estimated completion is 2026-02-20.
What conditions does trial NCT06354660 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT06354660?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06354660?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06354660 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
COMPLETED · Phase 3
-
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
COMPLETED · Phase 3
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.